|Bid||169.00 x 500|
|Ask||175.50 x 200|
|Day's Range||171.71 - 175.06|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.58|
|Dividend & Yield||4.60 (2.67%)|
|1y Target Est||N/A|
A Supreme Court ruling is likely to stir interest in more than a dozen biosimilars either approved for the market or in later stages of the R&D pipeline.
Categories: Yahoo FinanceGet free summary analysis Amgen, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Amgen, Inc. – GlaxoSmithKline plc Sponsored ADR, Gilead Sciences, Inc., Biogen Inc., Abbott Laboratories and Johnson & Johnson (GSK-US, GILD-US, BIIB-US, ABT-US and JNJ-US) that have also reported for ... Read more (Read more...)
Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha. The FDA will decide by Dec. 2 whether to allow Amgen to include data from a major clinical trial that showed Repatha significantly cut the risk of heart attack, stroke and death in addition to dramatically lowering bad LDL cholesterol, the company said.